&w=3840&q=100)
ICMR invites EoIs to undertake tech transfer, commercialise malaria vaccine
Developed by ICMR's Regional Medical Research Centre, Bhubaneswar (ICMR-RMRCBB), AdFalciVax aims to prevent plasmodium falciparum infections in humans and reduce community transmission of the parasite, which causes severe and potentially fatal malaria.
Non-exclusive tech transfer model proposed
The EoI outlines a non-exclusive agreement to be executed with one or more companies, enabling broader outreach and public health access. ICMR-RMRCBB will offer expert guidance and technical support across all stages of production to facilitate development and commercialisation.
The development process is expected to span at least seven years, divided into four stages, with a six-month buffer built into each stage.
While ICMR will provide scientific and technical support, the selected companies will be responsible for securing all regulatory approvals—from research and development to final commercialisation.
ICMR to retain IP and commercial rights
The Council clarified that it would bear no financial liability unless otherwise specified. Its institutes will, however, facilitate R&D and clinical studies within India.
In case of technology transfer, ICMR will retain sole ownership of the technology, including all underlying intellectual properties and commercial rights.
For joint development projects, any Background Intellectual Property (BGIP) will remain the exclusive property of the party that generated it.
Firms to pay royalty on net sales
Participating companies must share technical data with ICMR and engage in all discussions professionally and in mutual agreement.
'Subsequent to the execution of the agreement, such companies/manufacturers shall be responsible to pay the royalty at the rate of 2 per cent on net sales, according to the ICMR Guidelines for Technology Development Collaboration,' the Council stated.
India among top contributors to regional malaria cases
According to the World Health Organisation's World Malaria Report 2024, India accounts for half of the estimated malaria cases in the South-East Asia Region, which contributes 1.5 per cent of the global malaria burden.
India currently has access to two WHO-recommended malaria vaccines—Mosquirix, manufactured by GlaxoSmithKline (GSK), and R21/Matrix-M, made by the Serum Institute of India (SII). Both are primarily intended for children in regions with moderate to high malaria transmission.
Broader protection potential cited
An official familiar with the matter said AdFalciVax may offer broader protection and a lower risk of immune evasion compared to existing single-stage vaccines, based on preclinical data.
Pre-clinical validation of AdFalciVax was carried out in collaboration with ICMR's National Institute of Malaria Research (NIMR), other ICMR institutes, and the National Institute of Immunology in Delhi, an autonomous institute under the Department of Biotechnology.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
8 hours ago
- The Hindu
ICMR study finds only 28.5% of cancer patients receive radiotherapy in India
Radiotherapy is a cornerstone of cancer treatment in India, yet its expansion is hindered by high investment costs and effective planning, target estimation based on cancer burden are crucial to meet the radiotherapy demands of patients with cancer, noted a recent Indian Council for Medical Research (ICMR) study published in the UK-based BioMed Central (BMC) cancer journal early this month. Major shortfall in radiotherapy access India is faced with a substantial shortfall in radiotherapy utilisation across all cancer types and 28.5 percent of cancer patients receive radiotherapy, which is lower than the estimated optimal rate of 58.4 per cent. Breast, head and neck, lung and cervical cancer account for 60 per cent of India's radiotherapy needs. This underscores the need for interventions to meet the gap in machines required for equitable cancer care,'' said the study. Data from the Australian Collaboration for Cancer Outcomes Research and Evaluation (CCORE) were used by the researchers of ICMR-National Centre for Disease Informatics and Research, Bengaluru, for conducting the study. India accounts for 7 per cent of global cancer incidence, ranking third after China and the USA. By the end of 2025, the incidence of cancer in India is projected to reach 1.57 million cases, posing a significant public health challenge. Cancer burden in India As the fifth leading cause of death in the country, cancer demands urgent attention to improve prevention, diagnosis and treatment. Epidemiological data on stage, subsite and histology from the National Cancer Registry Programme were used to assess the optimal utilisation proportion for India. A sensitivity analysis was carried out. Similarly, the optimal radiotherapy fraction has also been calculated. These measures have been used to estimate the existing radiotherapy utilisation gap by comparing with the current radiotherapy utilisation from the cancer registry as well as to estimate the optimal radiotherapy machines required for the country. This study provides a comprehensive assessment of radiotherapy demand and existing gaps in radiotherapy utilisation and in the number of machines in India based on an epidemiological analysis of the cancer burden from the National Cancer Registry Programme. The study also recommended that India would require 1,585 to 2,545 machines, which may increase to a range of 2,016 to 2,291 external beam radiotherapy machines if the assumptions from previous benchmark studies are followed. This points towards an increasing demand for radiotherapy in the coming years as there is expected to be a 70-100 per cent increase in breast, head and neck and lung cancer in low and middle income countries (LMIC). Among the major indicated cancer sites, the deficit is more prominent in lymphoma and lung cancer (relative deficit of more than 70 per cent), followed by prostate, breast and oesophagus, said the study adding that radiotherapy, plays a crucial role in controlling tumour growth, reducing tumour size pre-surgery, and alleviating pain in advanced stages. Stating that high setup and operational costs are creating a significant gap between demand and resources, the study states that there is a need for greater investment to expand radiotherapy facilities to meet the growing demands of cancer patients. Urgent need to expand machines and reduce inequities The World Health Organization (WHO) recommends a minimum of one radiotherapy machine (external radiotherapy machine) per million population, with an optimal target of four per million, the study stated. For India's projected population of 1.45 billion in 2025, this translates to a need for a minimum of 1,450 machines. Yet, only 794 megavoltage (MV) machines are currently available. The shortfall is about 45 per cent from the minimal required standard, the study said. It further notes that aside from increasing the number of equipment, addressing the inequitable distribution of radiotherapy services is also crucial. To align with the country's cancer burden and ongoing control efforts, India must meet evidence-based targets for radiotherapy machine availability. The country is also ramping up efforts to develop and deploy affordable indigenous radiotherapy machines to improve access and reduce dependence on costly imports,' the study stated. The study notes that there is need for detailed situational study of radiation equipment deployment with its features and complexity, utilisation and throughput is required for informed planning and policymaking. Cancer screening and early detection programmes can facilitate the diagnosis of cancers at earlier stages. This could reduce the required quantum of radiotherapy shortly and thus, improve the overall survival of patients, the study said.
Indian Express
16 hours ago
- Indian Express
Knowledge Nugget: AdFalciVax and the fight against malaria — What you must-know for UPSC Exam
Take a look at the essential events, concepts, terms, quotes, or phenomena every day and brush up your knowledge. Here's your UPSC Current Affairs Knowledge Nugget for today on AdFalciVax and malaria. The Indian Council of Medical Research (ICMR) has invited the country's vaccine manufacturers to partner with it to launch and sell a malaria vaccine, AdFalciVax, that its Regional Medical Research Centre, Bhubaneshwar, has developed. In this context, let's know about this new vaccine and malaria. 1. AdFalciVax is a chimeric recombinant vaccine — a type of vaccine that uses different parts of the genes of a pathogen (in this case, Plasmodium) to create target proteins that trigger an immune response after being injected. 2. AdFalciVax uses two types of target proteins to prevent the spread of infection in two different ways. ↪ It uses the circumsporozoite protein (CSP) to prevent infection in the person who has been immunised. The CSP is produced during the sporozoite stage (when a parasite can infect a new host) and the liver stage (when a parasite enters liver cells, multiplies, and then infects red blood cells) of the parasite. 'Any immune response generated against these stages protects the immunised person from getting the infection.' Subhash Singh, project manager for development of the vaccine at the ICMR-Regional Medical Research Centre, Bhubaneswar told The Indian Express. ↪ The vaccine also uses the Pro6C protein, a fusion of parts of two different proteins — Pfs230 and Pfs48/45 — produced by Plasmodium falciparum. This protein prevents the spread of infection in the community. 3. Researchers have found that AdFalciVax provided more than 90% protection against infection in mice. The candidate vaccine has yet to undergo rigorous human trials, and the preliminary results have been obtained only through testing on animals. 4. The ICMR wants to partner with a company that can further develop its candidate vaccine, carry out human clinical trials, and scale up for commercial production. Although the ICMR will share the technology of developing AdFalciVax with the chosen company, it will continue to hold the intellectual property rights. Any intellectual property rights generated during the collaboration will be held jointly by the ICMR and the company. 5. Notably, AdFalciVax mainly targets two parts of Plasmodium falciparum, a pathogen that is the most common source of malaria in humans. In India, however, the disease is caused by Plasmodium vivax against which AdFalciVax is ineffective. To combat malaria, scientists have been working to develop a vaccine for decades but with limited success. Recently, two vaccines—RTS,S and R21—were approved for use, but their efficacy, at 75%, is quite low. That's why the announcement about ICMR's candidate vaccine has given new hope in the fight against the disease. World Malaria Day is observed every year on 25th April by the World Health Organisation to raise awareness and drive action against malaria. The theme for World Malaria Day 2025 is 'Malaria Ends With Us: Reinvest, Reimagine, Reignite.' 1. Having claimed millions of lives, malaria has been one of the deadliest diseases in human history. Currently, the disease kills about four lakh people annually, according to World Health Organization (WHO) figures. 2. Malaria is a parasitic infection transmitted by mosquitoes, typically causing symptoms such as fever, chills, night sweats, nausea, vomiting, and diarrhoea. In some cases, it can lead to severe complications such as seizures, fluid in the lungs, organ damage, and death. 3. It is most endemic in Africa — Nigeria, Congo, Tanzania, Mozambique, Niger, and Burkina Faso together account for more than half the yearly deaths. 1. India has demonstrated significant progress in reducing malaria cases and associated mortality in the country's high-endemic states, according to the findings of the World Health Organisation's (WHO) 'World Malaria Report 2024′. 2. 'India exited the HBHI [high-burden to high-impact] group officially in 2024 due to significant progress in reducing the malaria incidence and mortality observed in its high-endemic states,' the report observed. 3.'Nationwide, the number of estimated malaria cases in India decreased from 6.4 million in 2017 (the year before the HBHI's introduction) to 2 million cases in 2023 (69 per cent decrease). Similarly, the estimated malaria deaths decreased from 11,100 to 3,500 (68 per cent decrease) during the same period,' it said. 4. The HBHI refers to a targeted WHO initiative aimed at the most acutely malaria-impacted regions of the world, including several countries in Africa. Widespread resistance of malarial parasite to drugs like chloroquine has prompted attempts to develop a malarial vaccine to combat malaria. Why is it difficult to develop an effective malaria vaccine? (UPSC CSE 2010) (a) Malaria is caused by several species of Plasmodium (b) Man does not develop immunity to malaria during natural infection (c) Vaccines can be developed only against bacteria (d) Man is only an intermediate host and not the definitive host (Sources: India registers 'significant progress' in reducing malaria cases: WHO, WHO report says India reduces malaria caseload, deaths by 69% each) Subscribe to our UPSC newsletter. Stay updated with the latest UPSC articles by joining our Telegram channel – Indian Express UPSC Hub, and follow us on Instagram and X. 🚨 Click Here to read the UPSC Essentials magazine for July 2025. Share your views and suggestions in the comment box or at
Hindustan Times
16 hours ago
- Hindustan Times
400 frontline forest staff identified for zoonotic disease screening
PUNE: In a bid to enhance early detection and raise awareness about zoonotic diseases, nearly 400 forest and zoo staff members in Maharashtra have been shortlisted for medical screening. Registration for the screening process will begin soon, followed by a series of medical tests. The initiative aims to safeguard both wildlife and human populations by identifying potential risks of disease transmission among individuals most frequently in contact with animals. In a bid to enhance early detection and raise awareness about zoonotic diseases, nearly 400 forest and zoo staff members in Maharashtra have been shortlisted. ((PIC FOR REPRESENTATION)) Launched in January of this year, the program titled 'Building a Surveillance Model for Detecting Zoonotic Spillover in Increased Bird-Human Interaction Settings' adopts the one Health approach, a concept recognising the interconnection between people, animals, plants, and their shared environment. This pioneering project is a joint effort by the Maharashtra Forest Department, the Indian Council of Medical Research (ICMR), the National Institute of Virology (NIV), Pune, and Symbiosis International University. The program focuses on developing a real-time surveillance model to monitor zoonotic spillovers among frontline forest staff, zoo workers, bird sanctuary staff, and residents living near wetlands. Zoonotic diseases—those transmitted from animals to humans—are emerging as a significant global health threat. Notable examples include the Nipah virus, Ebola, Zika, SARS-CoV-2, Avian Influenza Virus (AIV), and Monkeypox. Despite the growing threat of zoonotic infections in India, scientists have noted a lack of comprehensive data on such diseases within the country. Since its launch, several awareness and sensitisation programs have already been conducted in districts such as Satara, Ahilyanagar, Solapur, and Junnar. Dr Satish Pande, a conservationist and researcher leading the sensitisation program, shared that the response to the initiative has been overwhelmingly positive. Following the sensitisation sessions, many frontline workers expressed eagerness to enrol. To date, 400 staff members have been identified for enrollment, with the registration process still ongoing. Once registration is complete, participants will undergo medical check-ups, including blood tests, to assess if they have been exposed to any viral infections via the presence of antibodies. Following the initial assessments, the health of each participant will be monitored over the next three years. In Maharashtra, four wild animals—including three tigers and one leopard—have died this year due to Avian influenza. Across India, at least three human deaths linked to zoonotic diseases have been reported. These cases highlight the increasing concern over zoonotic infections, particularly as viruses continue to breach species barriers. Frontline workers, who have frequent contact with both animals and local communities, are emerging as a potential link in the transmission chain. Dr Pande emphasised that this program will provide close health monitoring for these key personnel, making a significant contribution to both wildlife conservation and public health safety.
